Introduction micrornas (mirnas), which are endogenous non coding rnas of 19-25 nucleotides in length, are involved in the regulation of gene expression and are important in a wide range of physiological and pathological pro cesses. 1 the first gene encoding a mirna (lin-4) was discovered in 1993 in Caenorhabditis elegans 2 and was shown to negatively regulate lin14 protein expression at a specific time during development. Cloning of lin-4 revealed the presence of a 22nucleotide sequence, com plementary to a 3' untranslated region (utr) repeated sequence element of the lin-4 messenger rna (mrna) transcript, and led to the hypothesis that short nucleic acid sequences control protein expression by an anti sense rna-rna interaction.
2 the term mirna was not introduced until 2001 with the simultaneous pub lication of three related articles. [3] [4] [5] since then, an expo nentially increasing number of publications have shed light on various aspects of mirnas, ranging from their biogenesis to their functional roles in physiological and disease processes. in this article, we briefly describe the biogenesis and functions of mirnas and review recent advances in our understanding of their role in immunity. we summarize the accumulated clinical evidence of their potential use as biomarkers in rheumatic diseases and discuss their future potential, based on the available data for mirna biomarkers in nonrheumatic conditions.
Biogenesis of microRNAs
the first step in the biogenesis of mammalian mirnas is the generation of primary mirna transcripts (primir nas) 6 ( Figure 1 ). Primirnas are of variable sizes and can be tens of thousands of nucleotides in length. 7 Pri mirnas are cleaved in the nucleus to form hairpin pre mirnas (typically 70-100 nucleotides in length) 8 and are transported to the cytoplasm 9 for further process ing to become doublestranded rnas of 19-25 nucleotides in length. one strand is then loaded into a protein complex called risC (rnainduced silencing complex), 1, 10 which facilitates the binding of mirnas to their mrna targets. mirna binding can lead either to mrna degradation or to repression of translation; degradation occurs due to mrna deadenylation and destabilization, and repres sion of translation occurs during protein synthesis either at the initiation or postinitiation phase. 11 it should be noted that one mirna can control the translation of hundreds of genes simultaneously having an important role in finetuning protein expression. 12, 13 Mechanisms of action of microRNAs as the first mirnas to be discovered (lin-4 and let-7) were shown to exert their effect on the 3'utr of target mrnas, it was widely believed that mirnas exerted their effects through a perfect or imperfect com plementarity with sequences in the 3'utr only. the imperfect com plementarity required perfect target matching of the 2 nd through the 7 th nucleotides (seed sequence) starting from the 5' end of the mirna. Primarily through the seminal work of the rigoutsos group, 14 however, it was realized that mirnas can also target sequences within the 5'utr and the coding sequences of mrnas. this has been confirmed by research showing that genes involved in embryonic stem cell differentiation in mice (Nanog, Oct4, and Sox2) are downregulated by mirnas targeting their coding sequence. 15 similarly, mirna148 targets the coding sequence of Dna methyltransferase3b, an enzyme important for the de novo methylation of Dna. 16 there is also evidence that mirnas might target splice variants of specific genes, as exon-exon junctions have been shown to be specific mirna targets. 15 the implications of such a possibility are stunning and will add another layer of com plexity to the regulation of ex pression of specific is oforms within a system.
Functions of microRNAs
mirnas have been implicated in development, physio logical functions and disease processes. embryonic stem cell fate has been shown to be tightly regulated by the tem poral expression of specific mirnas. 15, [17] [18] [19] skin morpho genesis, 20 pancreas development, 21 muscle differen tiation, 22 cardiac growth, 23, 24 and neural develop ment 25 are all pro cesses in which mirnas have been impli cated. a large number of malignancies have been associ ated with altered mirna expressions. 26, 27 other nonmalignant diseases in which mirnas have been implicated include alzheimer disease, 28 neuro psychiatric disorders, 29 viral infections such as hepatitis 30 and aiDs, 31 primary biliary cirrhosis, 32 and rheumatic diseases including systemic lupus erythematos us (sle) [33] [34] [35] and rheumatoid arthritis (ra). [36] [37] [38] [39] as master regulators of gene expression, mirnas are instrumental in regulating immune system development, normal immune function and autoimmunity. expression profiles of hematopoietic cells have identified a number of mirnas that are differentially expressed in subsets of hematopoietic cells, the expression of which is tightly regulat ed during hematopoiesis and lineage differen tiation. 40 there are several reviews on the role of mirnas in immunity, and in autoimmune and rheumatic dis eases; [41] [42] [43] [44] therefore, in this article we focus on summarizing new developments relating to the potential use of mirnas as biomarkers.
the immune response in autoimmunity is charac terized by increased immune cell activation and failed or inefficient immune regulation, with type 17 helper t (t H 17) cells promoting autoimmunity and regulatory t (t reG ) cells exerting a protective effect. most likely it is a functional imbalance of these subtypes that leads to pathologic responses in autoimmune diseases. 45 the funda mental role of mirnas in regulating these cells has been shown in several studies. mir326 was identified in lympho cytes as a mirna associated with polariza tion towards the t H 17 cell lineage; the expression of this mirna correlated with disease activity and severity in mul tiple sclerosis and experimental autoimmune encephalo myelitis. 46 By contrast, mice unable to generate mirnas in their t reG cells develop severe autoimmune disease similar to mice deficient for t reG cells, owing to their inability to suppress activated t cells under inflammatory condi tions.
47 mir155 has been shown to be important for the maintenance of suppressor cell acti vity. 48 interestingly, mir155 also downregulates lipopolysaccharideinduced inflammatory pathways in human monocytederived Pri-miRNAs are cleaved in the nucleus to hairpin pre-miRNAs (typically 70-100 nucleotides in length) by Drosha, which is part of two multiprotein complexes including RNA helicases, heterogeneous nuclear ribonucleoproteins and a double-stranded RNA-binding protein. 8 Pre-miRNAs are then actively transported to the cytoplasm by the nuclear pore exportin-5 9 for further processing by the cytoplasmic endonuclease Dicer, which, in collaboration with RNA binding proteins, cleaves both strands of the pre-miRNA hairpin duplex generating a double-stranded RNA (19-25 nucleotides in length). One strand is then loaded into a protein complex called RISC, 1 which is a ribonucleoprotein complex consisting of an RNA helicase A and proteins including argonaute-2 and TRBP, 10 which facilitate the binding of miRNAs to their mRNA targets. MiRNA binding can lead either to mRNA degradation or to repression of translation. Abbreviations: miRNA, microRNA; mRNA, messenger RNA; pri-miRNAs, primary miRNA transcripts; RISC, RNA-induced silencing complex; TRBP, transactivation-response RNA-binding protein.
revIews dendritic cells, 49 and together with mir181b suppresses activationinduced cytidine deaminase expression, which is required for immunoglobulin gene diversification by B cells. 50, 51 adaptive B cell immunity is required for naive B cells to differentiate into effector B cells, such as memory cells and plasma cells. two studies, using slightly dif ferent approaches, described the role of known and hitherto unknown mirnas in Bcell differentiation. 52, 53 in one of these studies, mirna signatures of various lymphomas were analyzed and were shown to be predictive of lineage origin of lymphomas in over 95% of cases. 53 Regulation of microRNAs aberrant expression of mirnas can be caused by chromo somal abnormalities, insertion of foreign genetic material such as viral genomes, mutations or single nucleotide polymorphisms (snPs), as well as epigenetic changes and defects in mirna biogenesis pathways. 26 sequence homology profiling of approximately 250 snPs, which were unequivocally associated with 15 common human disorders, identified 72 snPs and 18 mirnas with an apparent propensity to target mrna sequences derived from a single proteincoding gene, KPNA1 (karyopherin alpha 1, also known as importin alpha 5), a component of the nuclear import pathway. each mirna in this elite set appeared to be linked to at least three common human diseases and had potential proteincoding mrna targets among the princip al components of the nuclear import pathway. 54 another characteristic of mirnas is the presence of mutations and polymorphisms, not only in the sequences of the mature mirnas, 55 but also in the sequences of the primirnas and the premirnas. 56 these sequence changes can affect the biogenesis of the mirnas or the action of mature mirnas on target sequences. variations in both the 5' and 3' end of the mature mirnas, which lead to variations in the length of mirnas, have also been identified by sequencing. 57 this has an important implication for the use of mirnas as biomarkers, since the assays used should clearly discriminate between those mirnas with polymorphisms and those without to allow the precise measurements of the levels of the mature mirnas. a snP of premir146a has been shown to modify the proapoptotic function of mir146a, by decreasing its expression levels, thus decreasing the well established inhibition of mir146a target genes such as IRAK1 (which encodes interleukin1 receptorassociated kinase 1) and TRAF6 (which encodes tumor necrosis factor receptorassociated factor 6). 58 this polymorphism possibly contributes to the genetic predisposition to papil lary thyroid carcinoma, 59 and is associated with the risk for hepatocellular carcinoma. 60 the study of associations between polymorphic or mutated mirnas and disease is at an early stage, but it seems promising.
Biomarkers in rheumatic diseases
rheumatology encompasses a wide variety of diseases ranging from those affecting primarily the joints, such as osteoarthritis, gout and the inflammatory arthritides, to systemic diseases, such as sle, vasculitis and systemic sclerosis, which typically affect multiple organs. many of these diseases have a heterogeneous and often unpredict able clinical course. Despite this heterogeneity, some fea tures, such as systemic inflammation, are common to many diseases, whereas others, such as the formation of autoantibodies, are restricted to specific conditions or a subset of patients with a certain disease.
a biomarker is a physical sign or cellular, bio chemical, molecular or genetic alteration by which a normal or abnormal biologic process can be recognized or monitored, or both, and that might have diagnostic or prog nostic utility. 61 Biomarkers have several potential applications in rheumatic diseases (table 1) . Genetic markers can predict or quantify the risk or the severity of diseases in populations or individuals. Classical exam ples include the increased risk of ankylosing spondylitis in carriers of the HLA-B27 allele, 62 and the association between the 'shared epitope' and ra. 63 an increasing number of genetic polymorphisms have been identified as risk factors for autoimmune diseases in general, 64, 65 as well as for specific diseases. 66 autoantibodies are fre quently used to establish or confirm a diagnosis. some, such as anticyclic citrullinated peptide (CCP) antibodies in ra, are fairly specific for a particular disease, 67 whereas others, such as antinuclear antibodies and antiro (ssa) antibodies are present, albeit at different frequencies and levels, in a number of conditions. 68 once a diagnosis is established, some biomarkers provide prognostic infor mation regarding disease progression and severity. For example, the combination of antiCCP positivity and the presence of the shared epitope defines a subset of patients with a severe form of ra, 69, 70 whereas the pres ence of specific autoantibodies define distinct subsets of inflammatory myopathies. 71 other biomarkers are used to monitor the degree of immunologic activity or inflamma tion. measures of levels of complement activation and of antidoublestranded Dna autoantibodies are commonly used to monitor disease activity in lupus nephritis, 72 and nonspecific markers of inflammation, such as the erythro cyte sedimentation rate or Creactive protein levels, are measured in many diseases. some of the biggest chal lenges, especially in the late stages of most chronic rheu matic diseases, include distinguishing between ongoing inflammation and irreversible organ damage, and assess ing the impact of comorbidities or the adverse effects of treatments. Probably most needed are biomarkers that predict response to a particular therapy. such markers MicroRNAs as biomarkers an ideal biomarker should be measurable in a repro ducible way, have high sensitivity and specificity for the clinical outcome of interest, and should reflect an important pathogenetic process. 61 mirnas are excit ing as potential biomarkers because they fulfill many of these criteria ( Figure 2 and table 2) . there are estab lished technologies for reliably measuring mirna levels: global mirna expression profiles can be determined by mirna micro array analysis using arrays containing all known human and many viral mirna sequences, whereas selected mirnas are best measured by quanti tative PCr. 73 mirnas have been shown to have the speci ficity and sensitivity required for clinical applications in some diseases. 74 similar to mrna or protein expression profiles, mirna levels reflect the underlying physiological state of cells and tissues, but have several advantages over mrnas or proteins as biomarkers. a single mrna is usually translated into a single protein; however, a single mirna is capable of regulating the translation of a multi tude of genes; therefore, it is expected that, compared with mrna expression analysis, a limited number of mirnas can be used as biomarkers, thereby reduc ing the complexity of global gene expression analysis. importantly, mirnas appear to be longlived in vivo, 75 and, in comparison with mrnas, are stable 76 and rela tively resistant to degradation by nucleases 77 in vitro. this stability, which is probably attributable to their small size and protection in mirna-protein complexes (either intracellularly or in microvesicles such as exo somes in blood and other biologic fluids), 78 enables them to be detected in clinical specimens from which mrna isolation is hampered because of the sensitivity of mrna to degradation. in fact, mirnas can be mea sured reproducibly from various sources, such as blood components, biological fluids (urine, 79 saliva
80
) and tissue samples. 81 the presence of mirnas in bio logical fluids dramatically increases their potential applications as biomarkers, and means that invasive procedures might eventually be unnecessary. Good correlations between serum and tissue mirna profiles have already been shown for several cancers. 77, [81] [82] [83] Furthermore, in contrast to mrnas, mirnas can be readily detected in formalin fixed paraffinembedded (FFPe) samples by micro array profiling or in situ hybridization. Formalin has been shown to crosslink nucleic acids that are larger than the mature mirnas and causes chemical modification to the nucleic acids making their detection difficult. By con trast, owing to their small size, mirnas are modified to a lesser extent than mrnas and can readily be amplified from formalinfixed tissues. 84 importantly, the expres sion levels of mirnas isolated from frozen samples and from FFPe samples correlate closely with each other. 85 arguably, using existing FFPe samples, which are a source of wellpreserved mirnas, with their associated clinical information, such as disease outcome, might lead to expedited biomarker discovery.
MicroRNAs in rheumatic diseases
rapidly accumulating evidence supports a central role for mirnas in normal and abnormal immune processes, but the exploration of their role in rheumatic diseases is in its infancy. a few studies have been published about the differential expression of mirnas and the role they might have in the etiology of rheumatic diseases, which we discuss here; the potential of mirnas as biomarkers in rheumatic diseases is a new area of research for which currently available data are limited (table 1) .
rheumatoid arthritis several reports have described altered mirna expression in the synovium of patients with ra. lipopolysaccharide activated ra fibroblastlike synoviocytes (Fls) over expressed mir346, which has been shown to negatively processes, combined with their relative stability and the availability of technology for their detection, makes them promising biomarker candidates for diagnosis, prognosis and disease activity in autoimmune diseases. In addition, studying the biologic impact of differences in miRNA expression between controls and various disease states will improve our insight of the pathogenesis of these conditions. Abbreviations: FFPe, formalin-fixed paraffin-embedded; miRNA, microRNA; mRNA, messenger RNA. regulate the interleukin (il)18 response of these cells. 37 in comparison with Fls from patients with osteo arthritis (oa), ra Fls expressed a considerably lower level of mir124a, which was identified as a key player in the regulation of proliferation and chemokine production by ra Fls. 36 mir146a has been shown to be highly expressed in human ra synovial tissue and its expres sion is induced by the proinflammatory cytokines tumor necrosis factor and interleukin1β. 39 interestingly, the cells with the highest levels of mir146a were CD68 + macrophages, CD3 + t cells and CD79a + B cells in the superficial and sublining layers of the synovium. 39 levels of mir146, mir155 and mir16 were found to be upregulated in the peripheral blood of patients with ra, and mir146 and mir16 levels were higher in patients with active (n = 8) rather than inactive (n = 3) disease, 38 suggesting that these mirnas could be potential markers of disease activity if these results are confirmed in a larger number of patients. osteoarthritis as mentioned, mir146a has been detected in the syno vium and Fls of patients with oa, albeit at a lower level than that seen in patients with ra. 86 levels of this mirna were considerably higher in oa cartilage in comparison with normal cartilage, although the levels decreased with the severity of cartilage degeneration. 87 the levels of mir146a correlated inversely with the levels of matrix metalloproteinase13, which is known to have a patho genic role in the cartilage destruction in oa, but a direct causal relationship between the two molecules was not demonstrated. therefore, the function of mir146 in the pathogenesis of oa remains unclear.
systemic lupus erythematosus there have been three main studies of mirna expres sion profiles in patients with sle. in the first study, peripheral blood mononuclear cell (PBmC) mirna profiles in healthy controls (n = 10) and patients with sle (n = 23) or idiopathic thrombocytopenic purpura (itP, n = 10) were compared. in comparison with the controls, 16 of the 331 human mirnas tested were differentially expressed (7 were downregulated and 9 upregulated) in sle, 35 whereas 19 mirnas were dif ferentially expressed in itP (14 downregulated and 5 upregulated). of the differentially expressed mirnas, 13 had the same expression pattern in sle and itP, 6 were downregulated in itP only, and 3 (mir184, mir198 and mir21) were upregulated or downregulated in sle with no change in itP. when comparing sle patients with active (sle Disease activity index score [sleDai] ≤12) and inactive (sleDai score ≥15) disease, eight mirnas were downregulated in the group with more active disease; interestingly, no mirna was expressed at higher levels in the active disease group. unfortunately, there are no longitudinal data to assess how well these mirnas correlate with disease activity in individuals over time. using a cutoff of twofold change in a second study, the same investigators identified 36 mirnas that were up regulated and 30 that were downregulated in the kidneys of patients with wHo Class ii lupus nephritis compared with normal controls. 34 the third study found that, of 156 mirnas analyzed, 42 were differentially expressed between controls and sle patients, with 7 being more than sixfold lower in sle. since type i interferon (iFn) is known to have a role in the etiology of sle, the authors explored the associ ation between the activation of the type i iFn pathway and the altered expression of mir146a, which has been reported to negatively regulate the innate immune system. overexpression of mir146a in primary PBmCs resulted in inhibition of tolllike receptor7 mediated iFnα and iFnβ production. in addition, transfection with synthetic mirna146a hairpin inhibitor to decrease endogenous mirna expression led to increased type i iFn production. the study also suggested that mir146a expression negatively correlated with sleDai and renal sleDai scores; 33 however, the correlation was rather weak (r values of -0.28 and -0.38, respectively).
sjögren syndrome we have generated mirna signatures from the minor salivary glands of patients with sjögren syndrome and normal controls; analysis of these expression profiles makes it possible to distinguish between these two popu lations as well as between subsets of patients with sjögren syndrome with lowgrade or highgrade inflammation. 88 we have also explored the presence of mirnas in exo somes isolated from parotid and submandibular saliva of patients with sjögren syndrome. Preliminary results showed that mirnas can be identified in saliva, which is of interest as this means it could be possible to obtain information from this target organ without the need for invasive methods, such as biopsies. [98] [99] [100] [101] in addition to diagnosis, mirna analysis has also been tested as a tool for the early detec tion of cancer or cancer recurrence, cancer classifica tion, and also as a marker of prognosis or response to therapy. expression profiling of 217 mirnas successfully identified the origin of 12 out of 17 poorly differen tiated tumors of unknown origin, whereas simultaneous pro filing of 16,000 mrnas did not accurately classify the tumors. 102 in another study involving the hierarchical clustering of mirna expression data from 540 samples of the six most frequent human cancers, mirna success fully identified their tissue origin, thus demonstrating the specificity of mirna profiling. 90 there is emerging evidence that mirnas can be used as prognostic markers. in chronic lymphocytic leukemia, a unique signature of 13 mirnas distinguished between patients with good or poor prognoses, 103 and in breast cancer differentially expressed mirnas were associ ated with invasive pathology 89 and were identified as indepen dent predictors of survival. 92 mirna expression pattern analysis was validated in a large study specifically designed to test mirnas as prognostic markers in colon adenocarcinomas; high levels of mir21 were associated with a poor therapeutic outcome and with poor survival in both the training (hazard ratio 2.5, 95% Ci 1.2-5.2) and validation cohorts (hazard ratio 2.4, 95% Ci 1.4-3.9), independent of clinical covariates, including tumor staging. 97 using a similar approach, hsamir205 was identified as a marker for squamous cell lung carcinoma, with a sensitivity of 96% and specificity of 90%. 81 the first commercial mirnabased diagnostic assays in oncology have recently become available in the usa. Based on the high discriminating power of mirnas, these assays can be used to differentiate between malig nant pleural mesotheliomas, peripheral adenocarcinoma of the lung, and metastatic carcinomas involving the lung and pleura, or to subclassify nonsmallcell lung carcinomas into squamous and nonsquamous histo logy subtypes. 104 in addition, by simultaneously measur ing the levels of 48 mirnas, these assays enable the identifica tion of the tissue of origin of metastatic cancers of unknown origin. in this context, elevated levels of various serum mirnas have been detected in prostate, 83 ovarian 105 and lung 77, 91, [106] [107] [108] cancers in comparison with normal serum.
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several papers have described the use of circulating exosomal mirnas as biomarkers in cancer. exosomes are small membranebound vesicles of endocytic origin released by cells, which are an important source of cellfree mirna in serum and other bodily fluids, such as urine 79 and saliva. 78 Comparisons between mirnas derived from circulating exosomes and mirna derived from tumors indicated that the mirna signatures from these two sources were not considerably different. 107 if this is con firmed, it is possible that exosomal mirnas from body fluids could be analyzed instead of mirnas from tissue or tumor samples, again meaning that in vasive procedures could be avoided. transplantation rejection of organ transplants is an immunemediated process and in many respects at the cellular and mol ecular level resembles inflammatory rheumatic diseases. a study in patients with acute kidney rejection, showed that renal allograft function could be predicted with a high level of precision using intragraft levels of mirnas as an indicator. 109 multiple sclerosis in patients with multiple sclerosis (ms), peripheral blood levels of mirna326 have been shown to be considerably higher in patients with the relapsing-remitting form of the disease than in healthy controls 46 or in patients with neuromyelitis optica, another demyelinating disease with overlapping clinical features but a different etiology to ms. 46 the levels of mirna326 were high in patients in the relapsing but not in the remitting phase of ms, and were attributable to an increased expression of this mirna326 in t H 17cells. 46 Conclusions mirnas possess many features of an ideal biomarker and, therefore, they represent a novel group of bio marker candidates for rheumatic diseases (Figure 2 ). some mirnas have already been validated as diag nostic or prognostic biomarkers in various malignant diseases, demonstrating their clinical utility. Given the central role of mirnas in the regulation of physiologic and pathologic processes, we can expect an exponential increase in publications about mirnas in various rheu matic diseases. some of these mirnas will undoubtedly be associated with distinct clinical characteristics, such as diagnosis or disease acti vity, making them interest ing candidates for further evaluation and testing in larger studies specifically designed to validate them as biomarkers.
Review criteria
Literature review was performed using PubMed. To identify papers published on the use of microRNAs as biomarkers we used the search terms "microRNA" AND "biomarker". To identify publications relating to autoimmune diseases we used the search terms "microRNA" AND "immunity", and "microRNA" AND "autoimmune"; this search was restricted to papers published in 2008 and 2009, to ensure the most recent papers were identified. All searches were limited to human studies published in english. 
